Research News
View articles by month and year
-
Tamoxifen Effectively Lowers Breast Cancer Risk in High-Risk Women Younger Than 55
An analysis of four large studies found that tamoxifen effectively reduces breast cancer risk in women younger than 55 at high risk. This benefit outweighed the costs and potential side effects of treatment.
-
Arimidex and Aromasin Equally Good at Reducing Recurrence Risk
A new study shows that Arimidex and Aromasin are equally good at reducing the risk of recurrence in postmenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer.
-
Aromatase Inhibitors Increase Risk of Heart Problems
Women diagnosed with early-stage, hormone-receptor-positive breast cancer who got 5 years of an aromatase inhibitor seem to be more likely to have heart problems compared to women who got 5 years of tamoxifen.
-
Radiation, Tamoxifen After DCIS Surgery Reduces Recurrence Risk
Research shows that radiation therapy and hormonal therapy after surgery for DCIS reduces the risk of being diagnosed with either another DCIS or invasive breast cancer in the future.
-
Arimidex Still Better Than Tamoxifen After Surgery to Reduce Recurrence Risk
After 10 years of follow-up, research shows that 5 years of Arimidex is better at reducing the risk of hormone-receptor-positive breast cancer recurrence than 5 years of tamoxifen.
-
New Guidelines Prefer Aromatase Inhibitors Over Tamoxifen
The American Society of Clinical Oncology has issued new guidelines on taking hormonal therapy medicines after breast cancer surgery.
-
Tamoxifen and Evista Both Good Choices to Reduce Risk
Both tamoxifen and Evista lower the risk of invasive and non-invasive breast cancer in women at high risk, and each medicine has benefits and risks.
-
Taking Antidepressant with Tamoxifen Reduces Tamoxifen’s Effectiveness
Research suggests that women taking the antidepressant Paxil at the same time as the hormonal therapy medicine tamoxifen are more likely to die from breast cancer than women taking tamoxifen who never took Paxil.
-
Radiation and Hormonal Therapy After DCIS Surgery Lowers Recurrence Risk
After DCIS surgery, radiation therapy seems to be better at lowering the risk of cancer in the same breast while hormonal therapy seems to be better at lowering the risk of cancer in the opposite breast.
-
Hormonal Therapy for Breast Cancer Seems to Reduce Lung Cancer Risk
A large Swiss study suggests that estrogen plays a role in the development, growth, and spread of lung cancer.
